Evidence map›Paper›PMID 39856215›Full record

ArticleScientific reports2025

Impact of frequent ARID1A mutations on protein stability provides insights into cancer pathogenesis.

Rajen K Goutam, Gangtong Huang, Exequiel Medina, Feng Ding, William J Edenfield, Hugo Sanabria

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. ARID1A and Its Impact Across the Hallmarks of Cancer.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Rajen K GoutamDepartment of Physics and Astronomy, Clemson University, Clemson, SC, USA.
Gangtong HuangDepartment of Physics and Astronomy, Clemson University, Clemson, SC, USA.
Exequiel MedinaDepartamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.
Feng DingDepartment of Physics and Astronomy, Clemson University, Clemson, SC, USA.
William J EdenfieldInstitute for Translational Oncology Research, Prisma Health, Greenville, SC, USA.
Hugo SanabriaDepartment of Physics and Astronomy, Clemson University, Clemson, SC, USA. hsanabr@clemson.edu.

Funding

Inhibition of Human Islet Amyloid Polypeptide AggregationR35GM145409 · NIGMS · CLEMSON UNIVERSITY · PI Feng Ding · 2022 to 2026
$2.0M
Impact of pathogenic missense mutations on the ARID domain of ARID1aR15CA280699 · NCI · CLEMSON UNIVERSITY · PI SANABRIA, HUGO · 2023 to 2023
$443k
NCI NIH HHS 1R15CA280699-01NCI NIH HHS R15 CA280699NIGMS NIH HHS 5R35GM145409-03NIGMS NIH HHS R35 GM145409
6 · The paper itself

Abstract

The ARID1A gene, frequently mutated in cancer, encodes the AT-rich interactive domain-containing protein 1 A, a key component of the chromatin remodeling SWI/SNF complex. The ARID1A protein features a conserved DNA-binding domain (ARID domain) of approximately 100 residues crucial for its function. Despite the frequency of mutations, the impact on ARID1A's stability and contribution to cancer progression remains unclear. We analyzed five frequent missense mutations R1020S, M1022K, K1047Q, G1063V, and A1089T identified in The Cancer Genome Atlas (TCGA) to assess their effects on the stability of the ARID domain using a hybrid experimental and computational approach. By combining computational stability from web server tools, the structural dynamics from replica exchange discrete molecular simulation (rexDMD), and thermal and chemical denaturation experiments, we found that the R1020S mutation severely decreases structural stability, making it the most impactful, while M1022K has minimal effect, and others lie in between. These findings enhance our understanding of the structural-functional relationship of ARID1A missense mutations at the molecular levels and their role in cancer pathogenesis. This research paves the way for identifying and categorizing which ARID1A mutations are most pathogenic, potentially guiding the development of targeted therapies tailored to specific mutation profiles in cancer treatment.

Indexed as

DNA-Binding ProteinsMutationNeoplasmsTranscription FactorsHumansMolecular Dynamics SimulationMutation, MissenseProtein StabilityARID1A protein, humanDNA-Binding ProteinsTranscription Factors

Identifiers

PMID39856215
PMCPMC11760938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.